The Luzzatto Group Wins a Landmark Ruling On Patent Term Extensions in Israel

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

The Luzzatto Group Wins a Landmark Ruling On Patent Term Extensions in Israel

Sponsored by

23LuzzattoGroupIsrael.png

Luzzatto Group talks about patent term extensions in Israel

On March 27, 2024, the Israeli District Court in Jerusalem rendered a significant ruling in a Novartis case concerning Patent Term Extensions (PTEs), which has broad implications for pharmaceutical patent owners. The court granted an appeal against a decision of the Registrar of Patents to revoke a PTE, thus establishing the principle that PTEs in Israel are linked to the active ingredient and not to the first pharmaceutical preparation relied on in filing the PTE application.

The case centered on the interpretation of PTE regulations in Israel, particularly regarding the relationship between the active ingredient and the first pharmaceutical preparation for which marketing approval was obtained. In general, PTEs are granted based on the registration of the first pharmaceutical preparation containing a novel active ingredient, allowing patent holders to extend their exclusive rights beyond the standard 20-year term.

In this specific instance, a patent was initially granted for a new active ingredient, which was the basis for a PTE relying on the registration of a pharmaceutical preparation containing the ingredient. However, the patent owner later registered two additional pharmaceutical preparations comprising the same active ingredient. Subsequently, the owner decided to abandon the registration for the first pharmaceutical preparation, leading to the revocation of the PTE by the Patent Registrar.

This decision was in line with a June 2022 ruling by the Tel Aviv District Court, which emphasized the dependency of PTEs on the marketing permit for the first pharmaceutical preparation.

However, the recent judgment from the Israeli District Court in Jerusalem, delivered by the Honorable Judge Dorot, introduced a significant departure from this narrow interpretation. The court ruled that under the relevant sections of Israeli Patent Law, the cancellation of the registration of the first preparation should not automatically invalidate the Extension Order. Instead, the crucial factor should be whether a registration of an additional preparation containing the same active ingredient exists.

Furthermore, the court underscored that PTEs are linked to the active ingredient itself rather than solely to the first pharmaceutical preparation that was initially registered.

This decision offers patent holders clarity and flexibility, allowing them to manage their patent portfolios more effectively. It ensures that patent rights are preserved even if the first pharmaceutical preparation is abandoned as long as alternative preparations containing the same active ingredient are registered before the abandonment.

Overall, this ruling sets a significant precedent in the interpretation of PTE regulations in Israel and provides valuable guidance for patent holders navigating the complexities of patent law concerning pharmaceutical preparations.

The Patent Owner was represented by Oren Mandler, Adv., Dr. Kfir Luzzatto, and Dr. Adina Cohen of The Luzzatto Group.

For more information about this ruling, please contact PTE@luzzatto.co.il

more from across site and SHARED ros bottom lb

More from across our site

In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Six hires across the IP spectrum reflect Orrick’s efforts to better serve tech clients across the IP lifecycle
David Stone, partner at White & Case, argues that the government’s planned reforms will modernise and futureproof UK design law, but leave two of the thorniest problems unresolved
Max Scott will join the firm’s IP transactions group in California, becoming the latest Weil IP partner to secure their future
Yonatan Drori, attorney at Drori-Stav IP in Israel, explains why foreign counsel must treat Israel’s patent disclosure requirements as an ongoing obligation, rather than a one-off formality
From Japan to Southeast Asia, domestic and regional firms picked up some of the biggest prizes, while key foreign players maintained momentum
Earlier this month, Managing IP had exclusively reported that the French arm of Taylor Wessing was minded to pull out of the deal
Our latest podcast examines how Weil’s IP practice evolved, where its practitioners could (and will) go next, and which firms and markets stand to benefit from the redistribution of talent
Gift this article